Both Amgen and Merck write quarterly checks and raise them every year, but only one has the portfolio depth to keep growing that payout through the next brutal round of patent expirations.
In the most recent trading session, Amgen (AMGN) closed at $385.65, indicating a +1.55% shift from the previous trading day.
Amgen has proven that it can manage market downturns fairly well. The company is also an excellent dividend stock.
September's market jitters highlight defensive stocks, ADM, AMGN and SUN, with low betas, high yields, raising 2026 guidance and improving earnings estimates.
Amgen NASDAQ: AMGN outlined its growth priorities, late-stage pipeline progress and capital-allocation framework during a Morgan Stanley conference, as newly appointed Chief Financial Officer Thomas Dittrich emphasized execution, financial discipline and cash-on-cash returns.
Amgen Inc. (AMGN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
ADM, COCO, AMGN and CNC offer defensive exposure as inflation, oil prices and weak consumer sentiment fuel market volatility.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
AMGN, BHC, CDNA and CNC offer defensive healthcare plays as inflation climbs and the Fed readies for a possible rate hike.